osteoarthritis
Research Roundup
Debbie Rigby rounds up the latest in research news Regular use of proton pump inhibitors and risk of type 2 diabetes A prospective analysis over 200,000 participants shows an association …
Professor Andrew McLachlan presents the recent trends and gaps identified in OA pain management
In this video, Professor Andrew McLachlan discusses how a patient’s health literacy can impact their choice of self-management strategies for OA symptoms and how a lack of condition awareness can …
Professor Andrew McLachlan explains how pharmacists play a critical role in identifying and supporting patients with Osteoarthritis
A recent study found only 3.5% of participants with self-reported OA symptoms sought advice from a pharmacist despite the critical role pharmacists play in helping patients on their pain management …
APP2021: Professor David Hunter on how pharmacists can facilitate more positive OA management outcomes
Osteoarthritis (OA) is a leading cause of disability that affects more than 3 million Australians. At APP 2021, Professor David Hunter, Florance and Cope Chair of Rheumatology, Professor of Medicine, the University of Sydney spoke …
Modified Release Paracetamol Up-schedule: Reviewing how the change is working in your pharmacy
Supported by GSK Consumer Healthcare All modified release paracetamol products have now changed from Pharmacy Medicine (Schedule 2) to Pharmacist Only Medicine (Schedule 3). Former PSA president, John Bell discusses …
Modified Release Paracetamol Up-schedule: Ensuring patients have a holistic treatment plan, with John Bell
Supported by GSK Consumer Healthcare All modified release paracetamol products changed from Pharmacy Medicine (Schedule 2) to Pharmacist Only Medicine (Schedule 3). Former PSA president, John Bell discusses how this …
Research Roundup
Debbie Rigby takes a look at the latest in research news Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation In this retrospective, cohort study …
Modified Release Paracetamol Up-schedule: What this means for you, with John Bell.
Supported by GSK Consumer Healthcare All modified release paracetamol products have now changed from Schedule 2 to Schedule 3 medicine. Former PSA president, John Bell discusses what this means for pharmacists …
Building a circle of support to break the cycle of pain
The way osteoarthritis (OA) is managed is evolving. The up-schedule of modified release (MR) paracetamol to Pharmacist Only (S3) on 1 June 2020 provides pharmacists with the opportunity to reassess …
Research Roundup
Debbie Rigby rounds up the latest in research news Amiodarone in the aged Amiodarone is a highly effective antiarrhythmic drug, but can have serious adverse effects, particularly in older patients. …
Research Roundup
Debbie Rigby takes a look at the latest in research news Safety of Proton Pump Inhibitors in patients receiving rivaroxaban or aspirin In a large placebo-controlled randomized trial, pantoprazole was …
Research Roundup
Debbie Rigby takes a look at the latest in research news Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy In this population-based …